

Applicants: Miragaya, et al.
Serial No.: Unassigned
Filing Date: Herewith
Docket No.: 976-28 PCT/US
Page 4

AMENDMENTS TO THE CLAIMS:

This listing of claims replaces the listing of claims in the application.

Listing of Claims:

CLAIMS

What is claimed is:

~~FORMULATIONS THAT CONTAIN AGENTS OF THROMBOLYTIC ACTION FOR RECTAL ADMINISTRATION~~

1. (Currently Amended) A formulation comprising ~~Formulations that contain~~ agents of thrombolytic action for ~~their~~ rectal administration ~~via rectal, the formulation comprising:~~
 - ~~Proteins~~ proteins and peptides with active thrombolytic and pharmacologically action;
 - ~~Oil~~ oil Base; and
 - ~~Active~~ active substances as: absorption promoters, protease inhibitors and preservers.
2. (Currently Amended) A ~~One~~ formulation ~~that~~ according to claim 1 characterized for containing proteins with thrombolytic action and/or anti-inflammatory, as streptokinase, (urokinase) and/or tisular activator of plasminogen.
3. (Currently Amended) A ~~One~~ formulation ~~that~~ according to claim 1 comprising ~~characterized for containing~~ recombinant streptokinase in a concentration of 50 000 – 1.500.000 UI/g.
4. (Currently Amended) A ~~One~~ formulation ~~that~~ according to claim 1 comprising ~~characterized for containing~~ natural streptokinase in a concentration of 50 000 – 1.500.000 UI/g.
5. (Currently Amended) A ~~One~~ formulation ~~that~~ according to claim 1 comprising ~~characterized for containing~~ urokinase in a concentration of 50 000 - 1.000.000 UI/g

6. (Currently Amended) A ~~One~~ formulation ~~that~~ according to claim 1 comprising ~~characterized for containing~~ tissue plasminogen activator in a concentration of 500000-50000000 UI/g.
7. (Currently Amended) A ~~One~~ formulation ~~that~~ according to claim 1-~~6~~ ~~characterized for containing~~ comprising promoters of mucosal absorption like sodium diclofenac and/or sodium salicylate.
8. (Currently Amended) A ~~One~~ formulation ~~that~~ according to claim 1 -~~6~~ ~~characterized for containing~~ comprising protease inhibitor.
9. (Currently Amended) A ~~One~~ formulation ~~that~~ according to claim 8 wherein ~~characterized because~~ the protease inhibitor is EDTA.
10. (Currently Amended) A ~~One~~ formulation ~~that~~ according to ~~claims~~ claim 1-~~7, 8 y 9~~ ~~characterized because~~ wherein the oil base is Witpsol H15.
11. (Currently Amended) A ~~One~~ formulation ~~that~~ according to ~~claims~~ claim 1-~~10~~ ~~characterized because~~ wherein the median ~~weigh~~ weight of the suppository is 1-3 g.
12. (Currently Amended) A ~~One~~ formulation ~~that~~ according to ~~claims~~ claim 1-~~11~~ ~~characterized for been~~ wherein the formulation is efficacious, without systemic effects for the treatment of hemorrhoidal disease.
13. (Currently Amended) A method for the treatment of hemorrhoids comprising rectally administering to a mammal ~~characterized by the use of~~ proteins and peptides with thrombolytic action ~~via rectal~~ in a suppository formulation .
14. (Currently Amended) A ~~One~~ method ~~that~~ according to claim 13 wherein ~~characterized because~~ the protein with thrombolytic action is streptokinase or peptides ~~derivates thereof from her.~~
15. (Currently Amended) A ~~One~~ method ~~that~~ according to claim 13 wherein ~~characterized because~~ the protein with thrombolytic action is ~~(urokinase)~~ urokinase or peptides derived thereof ~~derive from her.~~

16. (Currently Amended) ~~A One method that~~ according to claim 13 wherein ~~eharacterized~~ because the protein with thrombolytic action is ~~the~~ tissue plasminogen activator ~~of~~ or peptides derived ~~derive~~ from it.
17. (Currently Amended) The use of protein and peptides with thrombolytic action for the treatment of hemorrhoids for ~~eharacterized by it~~ use via rectal administration and in a suppository formulation.
18. (Currently Amended) The use according to ~~telaim~~ claim 17 wherein ~~where~~ the protein with thrombolytic action is streptokinase or peptides derive from it ~~her~~ for the treatment of hemorrhoids for ~~eharacterized by it~~ use via rectal administration and in a suppository formulation.
19. (Currently Amended) The use according to claim 17 ~~where~~ wherein the protein with thrombolytic action is urokinase (~~urekinase~~) or peptides derived ~~derive~~ from it for the treatment of hemorrhoids for ~~eharacterized by her~~ use via rectal administration and in a suppository formulation.
20. (Currently Amended) The use according to claim 17 ~~where~~ wherein the protein with thrombolytic action is ~~the~~ tissue plasminogen activator or peptides derived ~~derive~~ from it for the treatment of hemorrhoids for ~~eharacterized by it~~ use via rectal administration and in a suppository formulation.